Peoples Financial Services CORP. cut its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 27.4% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,628 shares of the biopharmaceutical company’s stock after selling 613 shares during the period. Peoples Financial Services CORP.’s holdings in Gilead Sciences were worth $116,000 as of its most recent SEC filing.
Other institutional investors have also recently bought and sold shares of the company. Rockland Trust Co. boosted its stake in Gilead Sciences by 16.7% in the first quarter. Rockland Trust Co. now owns 178,245 shares of the biopharmaceutical company’s stock worth $12,106,000 after buying an additional 25,551 shares in the last quarter. Linscomb & Williams Inc. boosted its stake in Gilead Sciences by 3.0% in the first quarter. Linscomb & Williams Inc. now owns 5,275 shares of the biopharmaceutical company’s stock worth $358,000 after buying an additional 154 shares in the last quarter. Berkshire Asset Management LLC PA bought a new stake in Gilead Sciences during the first quarter worth approximately $270,000. Sigma Planning Corp boosted its stake in Gilead Sciences by 7.7% in the first quarter. Sigma Planning Corp now owns 40,168 shares of the biopharmaceutical company’s stock worth $2,728,000 after buying an additional 2,889 shares in the last quarter. Finally, Hollencrest Securities LLC boosted its stake in Gilead Sciences by 119.8% in the first quarter. Hollencrest Securities LLC now owns 7,723 shares of the biopharmaceutical company’s stock worth $525,000 after buying an additional 4,210 shares in the last quarter. Institutional investors and hedge funds own 74.05% of the company’s stock.
Shares of Gilead Sciences, Inc. (NASDAQ:GILD) traded up 1.31% on Friday, reaching $75.94. The company had a trading volume of 8,954,646 shares. The company has a 50 day moving average of $69.98 and a 200-day moving average of $68.63. Gilead Sciences, Inc. has a 52 week low of $63.76 and a 52 week high of $82.10. The company has a market capitalization of $99.18 billion, a P/E ratio of 8.25 and a beta of 1.21. Gilead Sciences also saw some unusual options trading on Wednesday. Traders acquired 23,892 put options on the company. This represents an increase of 241% compared to the typical daily volume of 7,005 put options.
Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.11 by $0.45. Gilead Sciences had a return on equity of 66.07% and a net margin of 42.90%. The company had revenue of $7.14 billion for the quarter, compared to analysts’ expectations of $6.35 billion. During the same period last year, the firm earned $3.08 earnings per share. Gilead Sciences’s quarterly revenue was down 8.2% on a year-over-year basis. Analysts predict that Gilead Sciences, Inc. will post $8.72 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Thursday, September 28th. Stockholders of record on Friday, September 15th will be given a dividend of $0.52 per share. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.74%. The ex-dividend date is Thursday, September 14th. Gilead Sciences’s dividend payout ratio (DPR) is currently 22.58%.
ILLEGAL ACTIVITY NOTICE: This piece of content was reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of United States and international copyright law. The correct version of this piece of content can be read at https://stocknewstimes.com/2017/07/29/gilead-sciences-inc-gild-position-decreased-by-peoples-financial-services-corp-updated.html.
A number of equities research analysts have recently commented on the company. BMO Capital Markets reissued an “outperform” rating and issued a $82.00 target price (up from $72.00) on shares of Gilead Sciences in a research note on Thursday. Deutsche Bank AG reaffirmed a “buy” rating and set a $81.00 price objective (up from $79.00) on shares of Gilead Sciences in a research report on Thursday. Jefferies Group LLC reissued a “hold” rating and issued a $83.00 target price on shares of Gilead Sciences in a report on Thursday. Cowen and Company reissued an “outperform” rating and issued a $90.00 target price on shares of Gilead Sciences in a report on Thursday. Finally, Zacks Investment Research raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $84.00 target price on the stock in a report on Friday. Thirteen investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the stock. The company has an average rating of “Buy” and an average target price of $80.33.
In other news, insider John C. Martin sold 73,333 shares of Gilead Sciences stock in a transaction dated Monday, July 3rd. The stock was sold at an average price of $71.00, for a total transaction of $5,206,643.00. Following the sale, the insider now owns 3,199,969 shares in the company, valued at $227,197,799. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Gregg H. Alton sold 40,000 shares of Gilead Sciences stock in a transaction dated Friday, July 21st. The stock was sold at an average price of $74.00, for a total value of $2,960,000.00. Following the sale, the executive vice president now owns 137,488 shares in the company, valued at approximately $10,174,112. The disclosure for this sale can be found here. Insiders have sold 128,276 shares of company stock worth $9,190,610 in the last quarter. Insiders own 1.30% of the company’s stock.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
